Patient Enrollment Innovative Trends Using a Liquid Biopsy

Digital Event

Wednesday February 9, 2022 | 12.30pm – 3.30pm PT | 3.30pm - 6.30pm ET

Providing you with an outlook on the clinical disruption in Bladder, Lung and Breast Cancer influenced by MRD monitoring, join this Guardant Health workshop to discuss the latest MRD trends showcased by innovative use cases in early-stage disease.

Leveraging latest technological progress in focal amplification detection, the workshop will also delve deep in the uncovering of copy number alterations to enroll patients in relevant biomarker-informed late-stage cancer trials.


What will you discuss?

  • Unmet clinical and diagnostic needs in the adjuvant and neoadjuvant settings, as well as the potential of LBx to provide a solution
  • Targeted amplifications (e.g. ERBB2, MET) and the corresponding biomarker-informed treatments
  • Underlying technological (sensitivity vs. specificity in MRD, focal amplification vs. aneuploidy) and clinical challenges for a prospective trial roll-out and LBx considerations

Expert Speakers Include:

Pedram Razavi

Medical Oncologist

Memorial Sloan Kettering Cancer Center

David Chun Cheong Tsui

Division of Medical Oncology, Department of Medicine

University of Colorado Anschutz Medical Campus

Yoshiaki Nakamura

Department of Gastroenterology & Gastrointestinal Oncology

National Cancer Center Hospital East

David Gandara

Director, Thoracic Oncology

UC Davis Comprehensive Cancer Center

Memorial Sloan
medical campus
national east


Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets, and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ test for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.